Left bundle branch area pacing (LBBAP) has been found to be an effective and practical strategy for cardiac resynchronisation therapy (CRT), according to late-breaking science from the LECART trial presented today at the annual congress of the European Heart Rhythm Association (EHRA; 12–14 April 2026, Paris, France).
CRT involving implantation of a pacemaker device to help the chambers of the heart pump simultaneously is used in certain patients with heart failure who remain symptomatic despite guideline-recommended medical therapy and have electrical dyssynchrony. Specifically, it is a treatment option for patients with heart failure and reduced left ventricular ejection fraction (LVEF) who exhibit a dyssynchronous electrocardiogram (ECG) pattern called ‘left bundle branch block’.
“CRT with biventricular pacing is a well-established standard approach, but up to one-third of patients do not respond,” explained study presenter Jean-Benoît le Polain de Waroux (AZ Sint-Jan Hospital, Brugge, Belgium). “LBBAP has emerged as a more physiological approach to restore synchrony; however, there is a lack of data from head-to-head randomised trials. The LECART trial was designed to compare LBBAP with biventricular pacing, and uniquely incorporated the clinically meaningful endpoints of device-related complications requiring surgical reinterventions and failure to deliver resynchronisation.”
The prospective, randomised LECART trial was conducted at 11 high-volume centres in Belgium. Patients were eligible for inclusion if they had heart failure of New York Heart Association (NYHA) functional class II−IV, LVEF <40%, left bundle branch block and an indication for CRT according to current European Society of Cardiology (ESC) guidelines. Patients were randomised 1:1 to LBBAP or biventricular pacing. The primary endpoint—assessed over the first year—was a four-component composite consisting of death from any cause; heart failure hospitalisation; any device-related complication requiring a surgical reintervention; or failure to deliver the assigned resynchronisation therapy efficiently. All events were reviewed by an independent, blinded adjudication committee.
The 168 randomised patients had a mean age of 69 years, with 33% being female. Most patients (67%) had NYHA class II heart failure, and 77.5% were receiving at least three out of the four ESC guideline-recommended pillars of heart failure medication.
Over the first year after device implantation, the incidence of the primary outcome was 25% in the biventricular pacing group and 13% in the LBBAP group (hazard ratio, 2.14; 95% confidence interval [CI], 1.01–4.51; p=0.039). This difference was predominantly driven by a higher incidence of device-related complications with biventricular pacing versus LBBAP, as per respective rates of 15% and 1% (odds ratio, 6.76; 95% CI, 1.48–31.25; p=0.006), with no significant difference observed for death, heart failure hospitalisation and implant failure.
Additionally, the average procedure time was significantly longer with biventricular pacing versus LBBAP (90 minutes vs 76 minutes; p=0.005), while similar functional improvement was observed in both groups.
“This is the first randomised trial to demonstrate that LBBAP provides effective cardiac synchronisation while decreasing the need for surgical reintervention,” Le Polain de Waroux concluded. “The reduction in complications plus shorter procedure times with LBBAP are important both for patients and for the healthcare system as a whole.”
